Renal Transplantation Enhances the Sildenafil Citrate Effectiveness in Patients with Erectile Dysfunction. A Single-Center Perspective

To assess the efficacy and safety of Sildenafil citrate in the treatment of ED in (HD) compared to post-RT patients. A concurrent cohort prospective study to evaluate the efficacy of Sildenafil in the treatment of ED in 24 HD patients (Group A) and 13 patients with persistent ED one-year post-RT (Gr...

Full description

Saved in:

Bibliographic Details
Published in:	Transplantation proceedings Vol. 56; no. 6; pp. 1266 - 1272
Main Authors:	El Hennawy, Hany M., Safar, Omar, Al Faifi, Abdullah S., Shalkamy, Osama, Ali, Mohammed Abdelrahim, Ali, Hossam Hassanen, El Madawie, Mahmoud Z., Thamer, Saad, Almurayyi, Muath, Zaitoun, Mohammad F., Elzubair, Lina G.A., Elatreisy, Adel
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01-07-2024
Subjects:	Adult Aged Erectile Dysfunction - drug therapy Erectile Dysfunction - etiology Humans Kidney Transplantation Male Middle Aged Phosphodiesterase 5 Inhibitors - therapeutic use Prospective Studies Sildenafil Citrate - therapeutic use Treatment Outcome
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	To assess the efficacy and safety of Sildenafil citrate in the treatment of ED in (HD) compared to post-RT patients. A concurrent cohort prospective study to evaluate the efficacy of Sildenafil in the treatment of ED in 24 HD patients (Group A) and 13 patients with persistent ED one-year post-RT (Group B). The initial dose of Sildenafil was 25 mg, increased to 50 mg if there is an adequate response. An Arabic-translated International Index of Erectile Function (IIEF) questionnaire was completed one week before and after Sildenafil treatment. An IIEF erectile function score of 26 or an improvement of at least 10 points for the total IIEF score was considered a favorable response to Sildenafil. Group A included 22 patients with a mean age of 47.32 ± 7.013 years, whereas Group B included 13 patients with a mean age of 56.87 ± 9.612 years. The overall efficacy rate of Sildenafil was 40.9% and 76.9% in groups A and B, respectively. The post-treatment IIEF5-15 score increased from 11.1 ± 5.99 to 12.5 ± 6.41 (p = .458) and from 11.82 ± 7.534 to 21.91 ± 5.700 (p = .002) in groups A and B, respectively. In both groups, the duration of HD had no impact on ED improvement except in the post-RT non-responder subgroup. Hypertension, gastrointestinal symptoms, and flushing were both groups' most common side effects. RT could enhance the response to sildenafil in treating patients with ED. The outcome is better in younger post-RT patients with moderate and severe erectile dysfunction and shorter dialysis duration.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0041-1345 1873-2623 1873-2623
DOI:	10.1016/j.transproceed.2024.05.020